Sensei biotherapeutics announces submission of investigational new drug (ind) application for sns-101, a conditionally active vista-blocking antibody

Boston, march 21, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the submission of an investigational new drug (ind) application to the u.s. food and drug administration (fda) for a phase 1/2 clinical trial of sns-101, a conditionally active vista-blocking antibody, in patients with solid tumors.
SNSE Ratings Summary
SNSE Quant Ranking